简介:Depixus是法国一家遗传基因生物技术研发商,专注于开发MAGNA遗传分析技术,致力于解码动态基因组。 简介:Depixus是法国一家遗传基因生物技术研发商,专注于开发MAGNA遗传分析技术,致力于解码动态基因组。 融资历程1 导出 序号披露日期融资轮次融资金额企业估值比例投资方关联机构来源 1 2021-12-15 A轮 3540万美元 -...
which provides visualization and analysis of molecular interactions, including protein-protein interactions, small-molecule drug to RNA binding, and enzyme activity. This technology is used in the life sciences sector for research and development. Depixus was formerly known as PicoSeq. It was founded...
individual biomolecular interactions happening in parallel, generating a richness of data never seen before. Whether you’re studying protein-protein interactions, small-molecule drug to RNA binding, or enzyme activity, Depixus MAGNA One will open your eyes to what’s really happening at the ...
DepixusA轮 遗传基因生物技术研发商 https://depixus.com/ 关注(2)追踪笔记分享 标签&专辑 医疗健康生物技术生物技术和制药生物制药基因相关基因与生物技术制药 基本信息 Depixus是法国一家遗传基因生物技术研发商,专注于开发MAGNA遗传分析技术,致力于解码动态基因组。 欧洲-法国成立于: 2012-1公司规模: 300-1000...
depixus.com Total Raised $36.2M Investors Count 6 Funding, Valuation & Revenue 4 Fundings Depixus hasraised $36.2Mover4 rounds. Depixus'slatest funding roundwas aSeries A for $35.4MonDecember 15, 2021. Date Round Amount Investors Valuation ...
Recovers passwords from pixelized screenshots. Contribute to usgram/Depix development by creating an account on GitHub.
Depixus获得3060万欧元(3540万美元)的A轮融资 Depixus®是一家开发快速、准确和直接从DNA、RNA和蛋白质中提取多组信息的独特技术的生物技术公司。该公司近日宣布它在超额认购的A轮融资中筹集了3060万欧元。这些资金将用于进一步开发其专有的MAGNA™仪器系统、工作流程和试剂,以实现商业发布。本轮融资由Lansdowne ...
Depixus是法国一家遗传基因生物技术研发商,专注于开发MAGNA遗传分析技术,致力于解码动态基因组。近日获得3060万欧元A轮融资,Bpifrance、Lansdowne Partners联合领投,Casdin Capital、Arix Bioscience参投。 全国自考/成考新一轮扩招,2年制,免到校,学费2180,毕业双证...